drugset / Trial / NCT02375802

Adipose-Derived Stromal Cells (ASC's) for Pressure Ulcers

NCT02375802 ↗

Phase 1 Enrolling by invitation 12 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

This pilot study of 12 patients will test the safety and efficacy of applying autologous, adipose-derived stromal cells (ASCs), uncultured, on a Stage III or IV pressure ulcer or diabetic foot ulcers. Patients will undergo a minimal risk liposuction procedure to withdraw 50-100 cc of adipose tissue. The tissue would be processed to extract the stromal layer of cells that contain stem cells. The ASCs would be injected into a fibrin sealant to be applied to the wound. Patients would be followed for 6 weeks to assess wound healing and tolerance of the treatment.

Timeline

Start
2015-07
Primary completion
2027-12
Completion
2027-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Adipose derived stromal cells Cell therapy 5e+06 cells Topical

Indications